Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder
Sponsor: Sunshine Lake Pharma Co., Ltd.
Summary
This is a phase 2 and 3 adaptive design study for Mitizodone Phosphate,to find out an optimal dose in phase 2 period and confirm the result an efficacy and safety in phase 3 period.Dose-finding will be done after 8 weeks of double-blinded treatment in phase 2 period and will be assessed by both efficacy and safety from 3 dose groups of Mitizodone Phosphate.The dose be found in phase 2 period will be evaluated on efficacy and safety when compared with placebo in phase 3 period with a duration of 8 weeks treatment.The target subjects are patients with MDD.
Official title: A Phase II/III ,Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Adaptive Design Study Evaluating the Efficacy And Safety of Mitizodone Phosphate Tablets in the Treatment of Patient With Major Depressive Disorder
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
600
Start Date
2021-12-14
Completion Date
2027-11
Last Updated
2026-05-05
Healthy Volunteers
No
Conditions
Interventions
Mitizodone Phosphate tablets
Mitizodone Phosphate tablets will be administered with food.
Placebo-matching tablets
Placebo will be administered with food.
Locations (1)
Sunshine Lake Pharma Co., Ltd.
Dongguan, Guangdong, China